A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jun 18, 2019

HYPERCHOLESTEROLEMIA DRUG REPATHA® SC INJECTION RECEIVES SUPPLEMENTAL INDICATION APPROVAL AS MONOTHERAPY FOR TREATING HYPERCHOLESTEROLEMIA PATIENTS NOT SUITABLE FOR STATIN THERAPY

TOKYO (June 18, 2019) –, Amgen Astellas BioPharma K.K. (Headquarters, Tokyo; President and Representative Director: Steve Sugino, “Amgen Astellas”) and Astellas Pharma Inc. (Headquarters,...

Read more about HYPERCHOLESTEROLEMIA DRUG REPATHA® SC INJECTION RECEIVES SUPPLEMENTAL INDICATION APPROVAL AS MONOTHERAPY FOR TREATING HYPERCHOLESTEROLEMIA PATIENTS NOT SUITABLE FOR STATIN THERAPY
Jun 17, 2019

Launch of Gonax® 240 mg (New dosage form) in Japan for the treatment of prostate Cancer

TOKYO, June 17, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that it launched Gonax® 240 mg (generic name: degarelix acetate, “

Read more about Launch of Gonax® 240 mg (New dosage form) in Japan for the treatment of prostate Cancer
Jun 7, 2019

Bisono® Tape 2 mg, a Transdermal Patch of β1 Blocker, Launched in Japan

Tokyo: June 7, 2019 - TOA EIYO Ltd. (President: Atsuo Takahashi, Ph.D., “TOA EIYO”) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced...

Read more about Bisono® Tape 2 mg, a Transdermal Patch of β1 Blocker, Launched in Japan
Jun 4, 2019

Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

TOKYO and BOTHELL, Wash., June 3, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that...

Read more about Astellas and Seattle Genetics Announce Antibody-Drug Conjugate Enfortumab Vedotin Produced Tumor Response Rate of 44 Percent in Patients with Most Common Type of Advanced Urothelial (Bladder) Cancer
May 30, 2019

U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy1 -

TOKYO – May 30, 2019 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) approved a...

Read more about U.S. FDA Approves Supplemental New Drug Application Adding Overall Survival Data for XOSPATA® (gilteritinib)
May 10, 2019

Partial Amendments to the Articles of Incorporation

Read more about Partial Amendments to the Articles of Incorporation
May 10, 2019

Revision of Remuneration System for Directors

Read more about Revision of Remuneration System for Directors
May 10, 2019

Notice Regarding the Performance-linked Stock Compensation Scheme

Read more about Notice Regarding the Performance-linked Stock Compensation Scheme
Apr 25, 2019

Astellas Announces Cancellation of Treasury Shares

Read more about Astellas Announces Cancellation of Treasury Shares
Apr 25, 2019

Changes of Representative Director and Directors

Changes of Representative Director and Directors

Read more about Changes of Representative Director and Directors

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts